Gain Therapeutics, Inc. financial data

Symbol
GANX on Nasdaq
Industry
Pharmaceutical Preparations
Location
4800 Hampden Lane, Suite 200, Bethesda, MD
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 285 % -33.3%
Debt-to-equity 64.8 % +81.3%
Return On Equity -214 % -64.5%
Return On Assets -130 % -35.5%
Operating Margin -7.74K % -1.45%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.5M shares +101%
Common Stock, Shares, Outstanding 25.2M shares +99.3%
Entity Public Float 56.6M USD +45.9%
Common Stock, Value, Issued 2.52K USD +99.4%
Weighted Average Number of Shares Outstanding, Basic 19.2M shares +55.1%
Weighted Average Number of Shares Outstanding, Diluted 19.2M shares +55.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 55.2K USD +22.6%
Revenue from Contract with Customer, Excluding Assessed Tax 55.2K USD +47%
Research and Development Expense 11.7M USD +6.07%
General and Administrative Expense 10.2M USD -10.1%
Operating Income (Loss) -21.9M USD +1.89%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -21.5M USD +1.78%
Income Tax Expense (Benefit) 57K USD -54.5%
Net Income (Loss) Attributable to Parent -21.6M USD +2.08%
Earnings Per Share, Basic -1.3 USD/shares +28.6%
Earnings Per Share, Diluted -1.3 USD/shares +28.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.9M USD +168%
Marketable Securities, Current 2.02M USD -82.9%
Cash, Cash Equivalents, and Short-term Investments 12.7M USD
Assets, Current 18.5M USD +7.11%
Property, Plant and Equipment, Net 124K USD -10.6%
Operating Lease, Right-of-Use Asset 326K USD -41.8%
Assets 19.2M USD +5.12%
Accounts Payable, Current 2.05M USD +121%
Accrued Liabilities, Current 1.74M USD -0.63%
Liabilities, Current 6.52M USD +16.7%
Operating Lease, Liability, Noncurrent 134K USD -59.3%
Liabilities 7.41M USD +3.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 12.5K USD -90.7%
Retained Earnings (Accumulated Deficit) -60.8M USD
Stockholders' Equity Attributable to Parent 11.8M USD +6.24%
Liabilities and Equity 19.2M USD +5.12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.59M USD +15%
Net Cash Provided by (Used in) Financing Activities -146K USD -119%
Net Cash Provided by (Used in) Investing Activities 3.02M USD +43.3%
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 25.2M shares +99.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.16M USD +12.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17M USD +167%
Deferred Tax Assets, Valuation Allowance 12M USD +27.5%
Deferred Tax Assets, Gross 12.1M USD +27.4%
Operating Lease, Liability 321K USD -43.2%
Depreciation 8K USD 0%
Payments to Acquire Property, Plant, and Equipment 7.83K USD -72.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -21.7M USD +0.26%
Lessee, Operating Lease, Liability, to be Paid 326K USD
Property, Plant and Equipment, Gross 231K USD +9.57%
Operating Lease, Liability, Current 187K USD -20.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.02 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.43K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 84.7M USD +36%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 175K USD -22.2%
Depreciation, Depletion and Amortization 20.5K USD +6.68%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 235K USD -3.4%
Share-based Payment Arrangement, Expense 3.04M USD +8.49%
Operating Leases, Future Minimum Payments, Due in Three Years 57.9K USD -64.9%
Operating Leases, Future Minimum Payments Due 467K USD -31.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%